Details Basic Details Status Ongoing Last Updated Wednesday, November 6, 2024 Original Posting Date Tuesday, October 10, 2023 Health Outcome(s) COVID-19 hospitalization, Severe COVID-19 Purpose Drug and Outcome Analysis Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR No Analytic Code Link(s) (1) COVID-19 Hospitalization and Severe COVID-19 Infection Following Proton Pump Inhibitor (PPI) Use in Patients with Gastroesophageal Reflux Disease (GERD): An Inverse Probability of Treatment Weighting Analysis Result(s) (1) Utilization of Proton Pump Inhibitors (PPIs), Single-Agent H2 Receptor Antagonists (H2RAs), and Famotidine in Patients with Gastroesophageal Reflux Disease (GERD): A Descriptive Analysis